am -
pm ET

The Team

Alnylam Assist™ is comprised of dedicated, passionate individuals with diverse backgrounds and expertise in patient support. If you've decided to prescribe an Alnylam therapy to your patient, you can complete a Start Form and contact a Case Manager if you have any questions.

Alnylam Assist® Case Managers

Case Managers

Alnylam Assist™ is committed to the patient experience of those who start treatment with ONPATTRO® (patisiran). Patients are partnered with a Case Manager in their local area. Case Managers are trained professionals whose expertise is in helping patients get started on treatment and providing product support including:

Insurance benefit verification and connecting with a Field Reimbursement Director

Financial assistance enrollment for eligible patients*

Help ordering product

Connecting patients with a Patient Education Liaison (PEL)

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Alnylam Assist® Case Manager Natalie

Your Local Case Manager, Natalie

Alnylam Assist® Patient Education Liasons

Patient Education Liaisons

Patient Education Liaisons (PELs) are professionals with backgrounds in nursing who are experienced in educating patients and their families. PELs support patients and their families in a number of ways:

Engaging patients and families with educational resources

Answering questions about hATTR amyloidosis and treatment

Providing customized education, including one-on-one education or family meetings

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice

All diagnosis and treatment decisions should be made by the treating physician and their patients

Alnylam Assist® Field Reimbursement Directors

Field Reimbursement Directors

Field Reimbursement Directors (FRDs) are experienced professionals who provide education on the reimbursement process. They provide education to the patient's health care team on:

ONPATTRO billing and coding requirements

Payer requirements for ONPATTRO® coverage

Payer issue identification and resolution

Support throughout the Treatment Process

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Reaches Out. Step 3: Patient Support Provided.

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Reaches Out. Step 3: Patient Assistance.

What is the enrollment process for the Alnylam Assist™ program?

Everything you need to know about the enrollment process and its requirements, including what your patients need to know, can be found on this site. View the enrollment process ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›


Alnylam Assist® Start Form - To Print And Fax

& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle


Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).


ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.